Wu et al. identified and independently validated two reproducible [[subtype]]s associated with distinct [[molecular]] characteristics and clinical outcomes. The proliferative subtype, named [[Oligo1]], was characterized by more tumors of CNS WHO grade 3, as well as worse prognosis compared to the [[Oligo2]] subtype. Besides the clinicopathologic features, Oligo1 exhibited enrichment of cell proliferation, regulation of cell cycle and [[Wnt]] [[signaling pathway]]s, and significantly altered genes, such as [[EGFR]], [[NOTCH1]] and [[MET]]. In contrast, Oligo2, with favorable outcome, presented increased activation of immune response and metabolic process. Higher T cell/APC co-inhibition and inhibitory checkpoint levels were observed in Oligo2 tumors. Finally, multivariable analysis revealed this classification was an independent prognostic factor in oligodendrogliomas, and the robustness of these molecular subgroups was verified in the validation cohorts
((Wu F, Yin YY, Fan WH, Zhai Y, Yu MC, Wang D, Pan CQ, Zhao Z, Li GZ, Zhang W. Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes. EBioMedicine. 2022 Dec 14;87:104410. doi: 10.1016/j.ebiom.2022.104410. Epub ahead of print. PMID: 36525723; PMCID: PMC9772571.)).